MAPK8 and neoplasm: As a monotherapy, MAPK inhibitors are often ineffective and do not significantly affect the anti-proliferation of tumor cells, possibly by activating alternative EGFR downstream pathway targets to compensate for the inactivation of MAPK/JNK (i.e., adaptive rewiring) [68].